Barclays analyst Stephanie Davis raised the firm’s price target on Quest Diagnostics to $144 from $138 and keeps an Equal Weight rating on the shares. The company reported a fundamentally solid Q1 print and raised its fiscal 2024 outlook that “features healthy conservatism,” the analyst tells investors in a research note. The firm sees a beat/raise setup for 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024
- Quest Diagnostics raises FY24 adjusted EPS view $8.72-$8.97 from $8.60-$8.90
- Quest Diagnostics reports Q1 adjusted EPS $2.04, consensus $1.85
- Notable companies reporting before tomorrow’s open
- Quest Diagnostics launches blood biomarker test for Alzheimer’s diagnosis
